SSTR2

(redirected from somatostatin receptor 2)

SSTR2

A gene on chromosome 17q24 that encodes a G protein-coupled somatostatin receptor for somatostatin-14 and -28. It interacts with SHANK1 and is expressed in the brain and kidneys.
References in periodicals archive ?
Tarveda's lead Pentarin drug candidate, PEN-221, is a miniature drug conjugate that targets the somatostatin receptor 2 (SSTR2) for treatment of patients with neuroendocrine, small cell lung, prostate, and other cancers that express SSTR2.
Buck et al., "Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT," European Journal of Nuclear Medicine and Molecular Imaging, vol.
Considering that immunostaining for somatostatin receptor 2 antibody was scored as 3 (circumferential membranous reactivity in >50% of tumor cells), subcutaneous octreotide therapy was started at a dose of 100 [micro]g/day (Figure 4).
Although we did not perform SRS, strongly positive results for somatostatin receptor 2 were seen on immunohistochemical staining [14].
Mawrin et al., "Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas," The Journal of Clinical Endocrinology and Metabolism, vol.
Barde et al., "Critical role of somatostatin receptor 2 in the vulnerability of the central noradrenergic system: new aspects on Alzheimer's disease," Acta Neuropathologica, vol.
Buck et al., "Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in [sup.68]Ga-DOTATOC PET/CT," European Journal of Nuclear Medicine and Molecular Imaging, vol.
Kumar, "Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2. Co-immunoprecipitation and fluorescence resonance energy transfer analysis, " Cellular Signalling, vol.
Peng et al., "Mechanisms and influence of octreotide-induced regulation of somatostatin receptor 2 on hepatocellular carcinoma, " Chemotherapy, vol.
The company's lead pentarin clinical drug candidate, PEN-221, targets the somatostatin receptor 2 (SSTR2) for treatment of patients with tumors that express SSTR2 including neuroendocrine, small cell lung, and other cancers.
Planned development activities include completing Phase I dose-escalation and safety studies of PEN-221, a miniaturized conjugate targeting somatostatin receptor 2 (SSTR2), which is expressed in neuroendocrine and small cell lung cancers, and initiating and advancing its Phase 2A studies.
The company's lead Pentarin drug candidate, PEN-221, is a miniaturized drug conjugate that targets the somatostatin receptor 2 (SSTR2) for treatment of patients with neuroendocrine and small cell lung cancers.